Patents by Inventor Andrea DIFIGLIA

Andrea DIFIGLIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16
    Publication number: 20230355759
    Abstract: Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 9, 2023
    Applicant: CELULARITY INC.
    Inventors: Xuan GUO, Srinivas SOMANCHI, Rohit MATHUR, Shuyang HE, Qian YE, Xiaokui ZHANG, Salvatore ROTONDO, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA
  • POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220273716
    Abstract: Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use.
    Type: Application
    Filed: July 27, 2020
    Publication date: September 1, 2022
    Applicant: Celularity Inc.
    Inventors: Srinivas SOMANCHI, Xuan GUO, Shuyang HE, Rohit MATHUR, Xiaokui ZHANG, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA